Annexon, Inc. (ANNX) — Stock Valuation & Research

Annexon, Inc. is a biopharmaceutical company currently engaged in clinical trials, dedicated to the discovery and advancement of therapies for a variety of autoimmune, neurodegenerative, and ophthalmic conditions. Central to its approach is the C1q molecule, which initiates the classical complement pathway. The company targets this pathway to address specific disease mechanisms, such as those seen in antibody-mediated autoimmune disorders and complement-driven neurodegeneration. The company's developmental pipeline features several promising candidates. ANX005, a monoclonal antibody, is in…

ANNX key statistics

Explore ANNX's full valuation scorecard, price history, financial statements, insider and institutional ownership, and peer comparison on this page — free, no login required.